Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.
Poised to become the first company to achieve a regulatory filing for a cell therapy in autoimmune disease, Kyverna Therapeutics is building a pipeline-in-a-product to change the treatment paradigm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results